(Q40173489)

English

A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.

scientific article published on June 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

phase II clinical trial

0 references

maternal health

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Allison August

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Gregory M Glenn

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Eloi Kpamegan

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Somia P Hickman

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Dewal Jani

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Hanxin Lu

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

D Nigel Thomas

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Judy Wen

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Pedro A Piedra

9

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Louis F Fries

10

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

1 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

3749-3759

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

The burden of respiratory syncytial virus infection in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Vaccinations for pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

The Effects of Influenza Vaccination during Pregnancy on Birth Outcomes: A Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Duration of Infant Protection Against Influenza Illness Conferred by Maternal Immunization: Secondary Analysis of a Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in Texas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

A systematic review to calculate background miscarriage rates using life table analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Maternal Immunization Earlier in Pregnancy Maximizes Antibody Transfer and Expected Infant Seropositivity Against Pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Maternal Effects of Respiratory Syncytial Virus Infection during Pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Clinical Presentation and Birth Outcomes Associated with Respiratory Syncytial Virus Infection in Pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Influenza vaccination of pregnant women and protection of their infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Effectiveness of seasonal influenza vaccination during pregnancy in preventing influenza infection in infants, England, 2013/14.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Maternal influenza vaccination and effect on influenza virus infection in young infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Impact of maternal immunization on influenza hospitalizations in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Effectiveness of seasonal trivalent influenza vaccination against hospital-attended acute respiratory infections in pregnant women: A retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Effectiveness of maternal influenza immunization in mothers and infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.045

7 January 2021

Identifiers

10.1016/J.VACCINE.2017.05.045

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40173489&oldid=1486220339"